Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.
about
Recent developments in the management of invasive fungal infections in patients with oncohematological diseasesDefining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against AspergilluRodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infectionsRandomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.Micafungin in the treatment of invasive candidiasis and invasive aspergillosisDifferences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infectionsOptimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.Micafungin: a new echinocandin antifungal.Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosisThe pharmacology and clinical use of caspofungin.Nanoparticle transport across the blood brain barrier.Combination antifungal therapy: the new frontier.Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice.CNS pharmacokinetics of antifungal agents.Animal models: an important tool in mycology.Optimizing efficacy of Amphotericin B through nanomodification.Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysisAmphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactionsAnidulafungin treatment of candidal central nervous system infection in a murine modelParadoxical echinocandin activity: a limited in vitro phenomenon?Cerebral aspergillosis: tissue penetration is the key.Invasive aspergillosis in children with hematological malignancies.Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy.Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B.Combination antifungal therapy for invasive fungal infections in children and adults.Antifungal combination therapy for invasive aspergillosis.Real-time treatment guidelines: considerations during the Exserohilum rostratum outbreak in the United States.Reflections on the approach to treatment of a mycologic disaster.Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum.Fungal echinocandin resistance.In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp.Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.Efficacy of Amphotericin B at Suboptimal Dose Combined with Voriconazole in a Murine Model of Aspergillus fumigatus Infection with Poor In Vivo Response to the Azole.Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?Efficacy of voriconazole in Japanese quail (Coturnix japonica) experimentally infected with Aspergillus fumigatus.Vaccination with mannan protects mice against systemic aspergillosis.
P2860
Q28077381-A3D9F137-18A1-45AD-A952-32B689B45533Q33517581-4361AB5A-977B-470D-B495-8E570BC9CE8AQ33689767-138B3856-8D7D-44A5-9B9A-C7689C81177EQ34108585-DCF0E68B-0DE4-46B9-9A11-8206B1D71E28Q34151170-EC3F4742-1DE0-4674-9082-97503C382E0FQ35026516-661987AA-2B50-4037-BA27-DB0F7B65AC61Q35666612-7E067C8B-57D7-49B0-91E6-52D7EB28F397Q35746264-FB502AB6-6F69-4CFE-A22E-4BF755517A3AQ35840760-7833CB05-0E56-451F-8CDC-AF92C93D1E23Q36094939-632D99F1-D0C7-46B1-9720-59BEE9311A3FQ36693843-63E43386-4E27-4631-9EB7-6A599E2A3D5AQ36757621-221337B5-9422-4232-A5DD-844B3A97FCAFQ36788428-7F85B453-2E82-4680-B848-398D6A35DAA2Q36812347-28F76557-3F4E-420B-8661-14F4E67FDACDQ36895652-76605D11-5348-4034-82E5-2877F26698C9Q36895679-029AD6A7-3F1C-446B-874E-A68D52435E3FQ36909333-69951429-C180-46CE-BA5A-282FEF435B72Q37008692-A7E02EA4-D404-4EC9-AFBC-D1096D831AFDQ37178176-2ECB81E1-C54C-4136-8C21-EED2DD5D88C6Q37204192-6F4B97D4-E4E3-46FC-80FE-3164F330F51FQ37263780-ED7AA23D-5C13-4546-9E76-B25DB9620847Q37274734-D492E878-1BC1-42EA-AB10-8D0EC65EC4C0Q37405284-E2A2DBA2-BFE6-4E97-A1D2-D2096285C53BQ37405288-69748699-4B25-4667-A767-1E13E31863EBQ37854719-069DF7D8-CA60-41A6-A266-4FEDC9D72DD2Q37873552-FF6F54E3-48E3-43D2-A074-11860984729DQ38079194-8D4E4219-3B48-4ED6-8177-13C2FEC93954Q38102782-788CE7CD-CA60-4588-B9C0-4638AFA08C8AQ38232492-B36A9CDC-7330-47EC-969B-0050E0E64562Q39766609-36535317-147D-4593-91B4-AAC1A79AB640Q39767419-2D72872B-F7DC-4521-A617-D307BE2AB6B9Q41441699-351A191F-5C0B-48FE-87E9-B24910F69A05Q41789613-D11B6F89-28D0-41A5-A4FF-2685B22EE46EQ41848811-E6A55B80-CDF7-45C3-BF2B-6021D478A2FDQ42112008-13DC81CE-2311-4093-98FE-5FCF1126D0F1Q42217419-080D3639-6487-4A74-82E0-C46B569BD175Q42573050-D1950A2F-4EF1-4638-A415-440185F6AB1CQ42954068-12C67D72-DDE1-4989-8C57-858208771514Q45957532-A6F13508-C72E-4FA9-BC19-217171B669E4Q46143058-971C17F7-8093-417C-ABE4-C5F10561EE1A
P2860
Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Comparative efficacies of conv ...... nervous system aspergillosis.
@en
type
label
Comparative efficacies of conv ...... nervous system aspergillosis.
@en
prefLabel
Comparative efficacies of conv ...... nervous system aspergillosis.
@en
P2093
P2860
P1476
Comparative efficacies of conv ...... nervous system aspergillosis.
@en
P2093
David A Stevens
Karl V Clemons
Marife Espiritu
Rachana Parmar
P2860
P304
P356
10.1128/AAC.49.12.4867-4875.2005
P407
P577
2005-12-01T00:00:00Z